Author: Frediansyah, Andri; Tiwari, Ruchi; Sharun, Khan; Dhama, Kuldeep; Harapan, Harapan
Title: Antivirals for COVID-19: A critical review Cord-id: ifwrfdun Document date: 2020_7_28
ID: ifwrfdun
Snippet: No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess t
Document: No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.
Search related documents:
Co phrase search for related documents- abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
- abdominal pain and lopinavir ritonavir combination: 1
- active molecule and lopinavir ritonavir: 1
- active site and lopinavir darunavir: 1
- active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- active site and lopinavir ritonavir combination: 1
Co phrase search for related documents, hyperlinks ordered by date